Free Trial
→ The FED is losing the war on inflation (From WealthPress) (Ad)

Kymera Therapeutics Q2 2024 Earnings Report

Kymera Therapeutics logo
$36.81 -0.61 (-1.63%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Kymera Therapeutics EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$0.67

Kymera Therapeutics Revenue Results

Actual Revenue
$25.60 million
Expected Revenue
$12.55 million
Beat/Miss
Beat by +$13.05 million
YoY Revenue Growth
+55.20%

Kymera Therapeutics Announcement Details

Quarter
Q2 2024
Date
8/7/2024
Time
Before Market Opens

KYMR Upcoming Earnings

Kymera Therapeutics will be holding an earnings conference call on Thursday, February 27 at 8:30 AM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Conference Call Audio

Powered by Quartr

Kymera Therapeutics Earnings Headlines

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
February 20 at 11:23 AM | markets.businessinsider.com
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
January 30, 2025 | globenewswire.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 23, 2025 | WealthPress (Ad)
Kymera Therapeutics
January 17, 2025 | forbes.com
Kymera Therapeutics: Strategic Advancements and Strong Financials Bolster Buy Rating by Analyst
January 17, 2025 | markets.businessinsider.com
Bank of America Securities Remains a Hold on Kymera Therapeutics (KYMR)
January 16, 2025 | markets.businessinsider.com
See More Kymera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kymera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kymera Therapeutics and other key companies, straight to your email.

About Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR), a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

View Kymera Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles